Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer.
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aims were to assess response rate, toxicity, and survival in women treated with this combination. Among 49 patients, 34 objective responses (69%) were seen, with 10 complete responses (20%). Toxic effects were assessed in 186 treatment cycles. All patients had alopecia and nausea and vomiting. Other effects included myelosuppression, infection, reduction in renal function, and disturbance of consciousness. These data indicate that BIP is highly active against advanced and recurrent cervical cancer.
Buxton
E J
EJ
West Midlands Cancer Research Campaign Clinical Trials Unit, Birmingham, England.
Meanwell
C A
CA
Hilton
C
C
Mould
J J
JJ
Spooner
D
D
Chetiyawardana
A
A
Latief
T
T
Paterson
M
M
Redman
C W
CW
Luesley
D M
DM
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
D001761:Bleomycin; D002945:Cisplatin; D007069:Ifosfamide